50.22
50.22 (0%)
As of Feb 14, 2025
Tarsus Pharmaceuticals, Inc. [TARS]
Source:
Company Overview
Tarsus Pharmaceuticals, Inc is a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care.
| Country | United States |
| Headquarters | irvine, california |
| Phone Number | ( 949 ) 418-1801 |
| Industry | manufacturing |
| CEO | Bobak Azamian |
| Website | www.tarsusrx.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $183 |
| Operating Profit | $-120.6 |
| Net Income | $-115.6 |
| Net Cash | $-127.6 |
Profit Ratios
| Gross Margin | $183 |
| Operating Margin | -65.9 |
| Profit as % of Revenues | -158.3% |
| Profit as % of Assets | -36% |
| Profit as % of Stockholder Equity | -51.5% |
Management Effectiveness
| Return on Equity | -51.5% |
| Return on Assets | -30.7% |
| Turnover Ratio | 57% |
| EBITA | $-120.6 |
Balance Sheet and Cash Flow Measures
| Total Assets | $377 |
| Total Liabilities | $152.5 |
| Operating Cash Flow | $-83 |
| Investing Cash Flow | $-199.2 |
| Financing Cash Flow | $154.7 |
